183 related articles for article (PubMed ID: 24996830)
1. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Support Care Cancer; 2014 Dec; 22(12):3219-26. PubMed ID: 24996830
[TBL] [Abstract][Full Text] [Related]
2. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
3. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Assi H; Murray J; Boyle L; Rayson D
Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.
Shigeta K; Kosaka T; Yazawa S; Yasumizu Y; Mizuno R; Nagata H; Shinoda K; Morita S; Miyajima A; Kikuchi E; Nakagawa K; Hasegawa S; Oya M
Int J Clin Oncol; 2015 Jun; 20(3):605-12. PubMed ID: 25196861
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
Kamiya N; Suzuki H; Ueda T; Sato N; Nakatsu H; Mikami K; Sato N; Nomura K; Akakura K; Okano T; Ooki T; Naya Y; Ota S; Masai M; Ichikawa T
Int J Clin Oncol; 2014 Feb; 19(1):157-64. PubMed ID: 23299278
[TBL] [Abstract][Full Text] [Related]
7. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
8. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Poon DMC; Chan K; Chan TW; Ng B; Siu S; Ng J; Johnson D; Lee KC;
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():39-47. PubMed ID: 33860642
[TBL] [Abstract][Full Text] [Related]
9. Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer.
Hirasawa Y; Nakashima J; Sugihara T; Takizawa I; Gondo T; Nakagami Y; Horiguchi Y; Ohno Y; Namiki K; Ohori M; Tachibana M
Clin Genitourin Cancer; 2017 Feb; 15(1):176-181. PubMed ID: 27324052
[TBL] [Abstract][Full Text] [Related]
10. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
11. Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.
Maluf FC; de Oliveira FAM; Liedke PER; Brust L; Inocêncio CG; Monteiro FSM; Smaletz O; Cubero DI
Clin Genitourin Cancer; 2021 Jun; 19(3):e171-e177. PubMed ID: 33610484
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
Tsao CK; Galsky MD; Oh WK
Eur Urol; 2016 Nov; 70(5):707-708. PubMed ID: 27417033
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
15. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Peltekian S; Sajwani S; Wang X; Kanji S
Support Care Cancer; 2023 May; 31(5):311. PubMed ID: 37126153
[TBL] [Abstract][Full Text] [Related]
16. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.
Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
Support Care Cancer; 2014 Dec; 22(12):3275-85. PubMed ID: 25082364
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
19. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]